Will Intas’ Cut-Price Avastin Biosimilar Disrupt The Market?

 
• By Anju Ghangurde
  
Profit
WILL INTAS' BEVACIZUMAB PRICING CHANGE MARKET DYNAMICS?

More from Business

More from Scrip